GenSight Biologics S.A. GSGTF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -656.31% | -162.77% | -98.94% | -91.26% | -76.10% |
| Total Other Revenue | 5.66% | -20.12% | -39.28% | -37.86% | -35.72% |
| Total Revenue | -128.74% | -88.03% | -73.37% | -64.62% | -52.13% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -128.74% | -88.03% | -73.37% | -64.62% | -52.13% |
| SG&A Expenses | 6.10% | 0.05% | -9.30% | -21.79% | -30.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.64% | -24.42% | -34.04% | -30.22% | -26.18% |
| Operating Income | 9.70% | 17.06% | 27.51% | 25.80% | 23.61% |
| Income Before Tax | -8.82% | -1.60% | 10.50% | 19.16% | 24.43% |
| Income Tax Expenses | -22.67% | -99.35% | -122.91% | -92.37% | 134.38% |
| Earnings from Continuing Operations | -8.81% | -1.51% | 10.67% | 19.21% | 24.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.81% | -1.51% | 10.67% | 19.21% | 24.40% |
| EBIT | 9.70% | 17.06% | 27.51% | 25.80% | 23.61% |
| EBITDA | 6.53% | 13.55% | 24.06% | 21.43% | 18.37% |
| EPS Basic | 35.65% | 38.97% | 41.69% | 57.54% | 63.85% |
| Normalized Basic EPS | 35.73% | 38.83% | 41.51% | 57.52% | 63.86% |
| EPS Diluted | 35.65% | 38.97% | 41.69% | 57.54% | 63.85% |
| Normalized Diluted EPS | 35.73% | 38.83% | 41.51% | 57.52% | 63.86% |
| Average Basic Shares Outstanding | 61.17% | 63.32% | 57.98% | 67.92% | 82.21% |
| Average Diluted Shares Outstanding | 61.17% | 63.32% | 57.98% | 67.92% | 82.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |